# NCT02516241 (NCT02516241)

> Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

No report yet. It can be ordered.

- Drugs tested: durvalumab plus tremelimumab; durvalumab
- Indication: previously untreated unresectable stage IV urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02516241
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Urothelial Cancer
- Interventions: MEDI4736 (Durvalumab); Tremelimumab; Cisplatin; Carboplatin; Gemcitabine
- Enrollment: 1126
- Primary outcome: To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set
- Primary outcome: To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set

## Indexed commentary on NCT02516241 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02516241